Vertex Pharmaceuticals presented data at the European Cystic Fibrosis Conference, demonstrating the long-term benefits of treatment with CFTR modulators, including TRIKAFTA. The interim analysis of the largest real-world study of TRIKAFTA showed sustained improvement in lung function, reduction in pulmonary exacerbations frequency, and lower rates of lung transplant and death for people with cystic fibrosis.